Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 15/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1948726 | 0.86 | MAOB (0.43) | SLC6A4 | |
| SCHEMBL1951907 | 0.82 | SLC6A4 (0.45) | CCR5SLC6A4STAT3PTGER1 | |
| SCHEMBL1948653 | 0.82 | SMN1; SMN2 (0.47) | PTGER1 | |
| SCHEMBL1948704 | 0.77 | IDO1 (0.54) | CCR5SLC6A4STAT3NPSR1PTGER1 | |
| SCHEMBL13673987 | 0.75 | MAOB (0.40) | SLC6A4PTGER1 | |
| SCHEMBL1906514 | 0.75 | KMT2A (0.37) | CCR5NPSR1 | |
| SCHEMBL13517128 | 0.74 | SLC6A4 (0.39) | SLC6A4NPSR1PTGER1 | |
| SCHEMBL13321705 | 0.73 | CCR5 (0.68) | CCR5SLC6A4STAT3NPSR1 | |
| SCHEMBL18920768 | 0.71 | CCR5 (0.64) | CCR5SLC6A4STAT3NPSR1 | |
| SCHEMBL13516738 | 0.71 | NPC1 (0.50) | SLC6A4NPSR1PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | claimed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | claimed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323740-A1 | IDO Inhibitors | IDO1, IDO2, INMT | CCR5 256/4885SLC6A4 1207/4885STAT3 1657/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | CCR5 256/4885SLC6A4 1207/4885STAT3 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.